Evidence map›Paper›PMID 36846105›Full record

ArticleOphthalmology science2023

Macular Telangiectasia Type 2: A Classification System Using MultiModal Imaging MacTel Project Report Number 10.

Emily Y Chew, Tunde Peto, Traci E Clemons, Ferenc B Sallo, Daniel Pauleikhoff, Irene Leung, Glenn J Jaffe, Tjebo F C Heeren, Catherine A Egan, Peter Charbel Issa and 5 more

Abstract read
In one paragraph

Article in Ophthalmology science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Macular telangiectasia type 2: An update.The Journal of international medical research · 2026
    Review
  4. Article
  5. Ethnic comparison of MacTel over 5 years follow up.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Observational
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Genetic Background of Macular Telangiectasia Type 2.International journal of molecular sciences · 2025
    Review
  17. Observational
  18. Quantification of vascular changes in macular telangiectasia type 2 with AngioTool software.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Tunde PetoCentre for Public Health, Queen's University, Belfast, United Kingdom.
Traci E ClemonsThe Emmes Corporation, Rockville, Maryland.
Ferenc B SalloJules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
Daniel PauleikhoffDepartment of Ophthalmology, St. Franziskus Hospital Muenster, Muenster, Germany.
Irene LeungNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL, Institute of Ophthalmology, London, United Kingdom.
Glenn J JaffeDepartment of Ophthalmology, Duke University, Durham, North Carolina.
Tjebo F C HeerenNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL, Institute of Ophthalmology, London, United Kingdom.
Catherine A EganNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL, Institute of Ophthalmology, London, United Kingdom.
Peter Charbel IssaOxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Konstantinos BalaskasNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL, Institute of Ophthalmology, London, United Kingdom.
Frank G HolzDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Alain GaudricDepartment of Ophthalmology, Université Paris Cité. APHP, Hôpital Lariboisière, Paris, France.
Alan C BirdNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL, Institute of Ophthalmology, London, United Kingdom.
Martin FriedlanderThe Lowy Medical Research Institute and the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.

Funding

Phase 2 Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136)ZIAEY000536 · NEI · NATIONAL EYE INSTITUTE · PI CHEW, EMILY Y · 2014 to 2025
$635k
A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2ZIAEY000566 · NEI · NATIONAL EYE INSTITUTE · PI CHEW, EMILY Y · 2019 to 2025
$282k
6 · The paper itself

Abstract

Purpose: To develop a severity classification for macular telangiectasia type 2 (MacTel) disease using multimodal imaging. Design: An algorithm was used on data from a prospective natural history study of MacTel for classification development. Subjects: A total of 1733 participants enrolled in an international natural history study of MacTel. Methods: The Classification and Regression Trees (CART), a predictive nonparametric algorithm used in machine learning, analyzed the features of the multimodal imaging important for the development of a classification, including reading center gradings of the following digital images: stereoscopic color and red-free fundus photographs, fluorescein angiographic images, fundus autofluorescence images, and spectral-domain (SD)-OCT images. Regression models that used least square method created a decision tree using features of the ocular images into different categories of disease severity. Main Outcome Measures: The primary target of interest for the algorithm development by CART was the change in best-corrected visual acuity (BCVA) at baseline for the right and left eyes. These analyses using the algorithm were repeated for the BCVA obtained at the last study visit of the natural history study for the right and left eyes. Results: The CART analyses demonstrated 3 important features from the multimodal imaging for the classification: OCT hyper-reflectivity, pigment, and ellipsoid zone loss. By combining these 3 features (as absent, present, noncentral involvement, and central involvement of the macula), a 7-step scale was created, ranging from excellent to poor visual acuity. At grade 0, 3 features are not present. At the most severe grade, pigment and exudative neovascularization are present. To further validate the classification, using the Generalized Estimating Equation regression models, analyses for the annual relative risk of progression over a period of 5 years for vision loss and for progression along the scale were performed. Conclusions: This analysis using the data from current imaging modalities in participants followed in the MacTel natural history study informed a classification for MacTel disease severity featuring variables from SD-OCT. This classification is designed to provide better communications to other clinicians, researchers, and patients. Financial Disclosures: Proprietary or commercial disclosure may be found after the references.

Indexed as

BCVA, best-corrected visual acuityBLR, blue light reflectanceCART, Classification and Regression TreesCF, color fundusClassificationClassification and Regression Trees (CART)EZ, ellipsoid zoneFAF, fundus autoflorescenceFLIO, fluorescence lifetime imaging ophthalmoscopyMachine learningMacTel, macular telangiectasia type 2Macular telangiectasia type 2Neurovascular degenerationNHOR, natural history observation registryNHOS, natural history observation studyOCTA, OCT angiographySD-OCT, spectral domain-OCTVA, visual acuity

Identifiers

PMID36846105
PMCPMC9944556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.